NetScientific (GB:NSCI) has released an update.
NetScientific Plc reports a 3% holding in PDS Biotechnology, which is set to initiate the Phase 3 VERSATILE-003 trial in Q4 2024 for an innovative HPV16-positive head and neck cancer treatment. The FDA has supported the development strategy for PDS Biotech’s Versamune-based immunotherapy, which includes double and triple combination treatments and has received Fast Track designation. Preparatory work for the trial, which will focus on overall survival as its primary endpoint, is already underway with significant support from key opinion leaders.
For further insights into GB:NSCI stock, check out TipRanks’ Stock Analysis page.
